Aligos Therapeutics, developing several different hep B and NASH treatments, files for $100M IPO raise

Another biotech filed to go public late Friday as the 2020 IPO party rages on.

Aligos Therapeutics, focusing on chronic hepatitis B and NASH, submitted its S-1 paperwork to the SEC with a goal of raising $100 million. The company’s lead candidate is known as a STOPS molecule, or an S-antigen transport-inhibiting oligonucleotide polymer, and started a Phase I study for CHB in August.